Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Zynyz (retifanlimab-dlwr)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Incyte, MacroGenics

Drug class:

PD1 inhibitor

Related drugs:

pembrolizumab (727)

nivolumab (607)

sintilimab (115)

toripalimab-tpzi (88)

camrelizumab (85)

tislelizumab-jsgr (84)

dostarlimab-gxly (43)

cemiplimab-rwlc (29)

zimberelimab (20)

pucotenlimab (12)

cadonilimab (10)

serplulimab (7)

PF-06801591 (6)

JNJ-63723283 (5)

nivolumab/relatlimab-rmbw (4)

geptanolimab (3)

iparomlimab/tuvonralimab (3)

ivonescimab (3)

CMAB 819 (nivolumab biosimilar) (0)

EBV-specific anti-PD1 TCR-T cells (0)

enlonstobart (0)

prolgolimab (0)

NY-ESO-1 TCR-T cell therapy (0)

prolgolimab/nurulimab (0)

nivolumab and hyaluronidase-nvhy (0)

PD-1-KO-T cell injection (0)

PF-07209960 (0)

Undisclosed PD-1 inhibitor (0)

Undisclosed anti PD-1 mAb (0)

anti-PD-1 antibody (0)

›

No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	retifanlimab-dlwr Sensitive: A1 - Approval retifanlimab-dlwr Sensitive : A1	retifanlimab-dlwr Sensitive: A1 - Approval retifanlimab-dlwr Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	retifanlimab-dlwr Sensitive: C2 – Inclusion Criteria retifanlimab-dlwr Sensitive : C2	retifanlimab-dlwr Sensitive: C2 – Inclusion Criteria retifanlimab-dlwr Sensitive : C2
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	retifanlimab-dlwr Sensitive: C2 – Inclusion Criteria retifanlimab-dlwr Sensitive : C2	retifanlimab-dlwr Sensitive: C2 – Inclusion Criteria retifanlimab-dlwr Sensitive : C2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	retifanlimab-dlwr Sensitive: C2 – Inclusion Criteria retifanlimab-dlwr Sensitive : C2	retifanlimab-dlwr Sensitive: C2 – Inclusion Criteria retifanlimab-dlwr Sensitive : C2
HER-2 positive + PD-L1 expression	Gastroesophageal Cancer	HER-2 positive + PD-L1 expression	Gastroesophageal Cancer	margetuximab-cmkb + retifanlimab-dlwr Sensitive: C3 – Early Trials margetuximab-cmkb + retifanlimab-dlwr Sensitive : C3	margetuximab-cmkb + retifanlimab-dlwr Sensitive: C3 – Early Trials margetuximab-cmkb + retifanlimab-dlwr Sensitive : C3
IDH wild-type	Glioblastoma	IDH wild-type	Glioblastoma	bevacizumab + retifanlimab-dlwr Sensitive: C3 – Early Trials bevacizumab + retifanlimab-dlwr Sensitive : C3	bevacizumab + retifanlimab-dlwr Sensitive: C3 – Early Trials bevacizumab + retifanlimab-dlwr Sensitive : C3